Endocrine Pharmacology: Calcium Homeostasis and Drugs Affecting Bone Mineral Density

Introduction/Overview

Calcium homeostasis represents a critical physiological process regulated by a complex endocrine network. Within this network, parathyroid hormone (PTH), vitamin D metabolites, calcitonin, and sex steroid hormones collaboratively maintain serum calcium concentrations and influence bone remodeling dynamics. Disruption of these regulatory pathways frequently manifests as osteoporotic bone loss, contributing to increased fracture risk across diverse populations. Pharmacologic manipulation of calcium metabolism and bone turnover has become a cornerstone of clinical management for osteoporosis, Paget disease, hypercalcemia, and other skeletal disorders. Understanding the mechanistic basis and therapeutic profiles of agents that modulate calcium balance and bone mineral density (BMD) is essential for optimizing patient outcomes, mitigating adverse events, and navigating drug–drug interactions.

Learning objectives for this chapter include:

• Identify the primary endocrine regulators of calcium homeostasis and their roles in bone remodeling.
• Classify pharmacologic agents that influence bone mineral density according to mechanism of action and chemical structure.
• Describe the pharmacodynamic and pharmacokinetic properties of key anti‑osteoporotic drugs.
• Evaluate therapeutic indications, contraindications, and safety considerations for these agents.
• Recognize potential adverse effects and drug interactions that may influence clinical decision‑making.

Classification

Drug Classes Targeting Calcium Homeostasis and Bone Remodeling

• Vitamin D Analogs – 1α‑hydroxylated compounds that enhance intestinal calcium absorption.
• Parathyroid Hormone (PTH) Analogs and Mimetics – Anabolic agents that stimulate bone formation.
• Bisphosphonates – Osteoclast‑inhibiting agents that suppress bone resorption.
• Denosumab – A monoclonal antibody that neutralizes receptor activator of nuclear factor‑κB ligand (RANKL).
• Selective Estrogen Receptor Modulators (SERMs) – Estrogen‑like agents with bone‑protective properties.
• Calcitonin – A peptide hormone that directly inhibits osteoclast activity.
• Hormone Replacement Therapy (HRT) – Estrogen and progesterone combinations that modulate bone turnover.
• Others – Agents such as strontium ranelate, romosozumab (Wnt pathway agonist), and novel bisphosphonate derivatives.

Chemical Classification of Anti‑osteoporotic Agents

Within the bisphosphonate class, further subdivision is based on nitrogen content:

• Non‑nitrogen‑containing bisphosphonates – e.g., etidronate, clodronate; primarily disrupt osteoclast ATP synthesis.
• Nitrogen‑containing bisphosphonates – e.g., alendronate, risedronate, ibandronate, zoledronic acid; inhibit farnesyl pyrophosphate synthase within the mevalonate pathway, leading to osteoclast apoptosis.

Vitamin D analogs are classified by structural modifications that influence potency and half‑life, such as calcitriol, alfacalcidol, and eldecalcitol. PTH analogs (teriparatide, abaloparatide) are recombinant peptides that mimic native PTH(1–34) or PTHrP(1–34) sequences. Denosumab is a humanized IgG2 monoclonal antibody, while SERMs such as raloxifene and bazedoxifene exhibit selective estrogenic activity across different tissues.

Mechanism of Action

Vitamin D Analogs

Vitamin D exerts its effects through binding of the vitamin D receptor (VDR), a nuclear hormone receptor expressed in enterocytes, osteoblasts, and osteoclasts. Upon ligand binding, VDR heterodimerizes with the retinoid X receptor (RXR) and translocates to the nucleus, where it regulates transcription of calcium‑binding proteins such as calbindin D9k and intestinal calcium transporters. This genomic action results in increased intestinal calcium absorption and mobilization from bone. In osteoblasts, VDR activation also promotes mineralization and modulates osteoclast differentiation via osteoprotegerin (OPG) production. Non‑genomic actions, mediated by membrane‑associated VDR complexes, may rapidly influence calcium fluxes and bone cell signaling.

PTH Analogs and Mimetics

PTH analogs bind to the type 1 PTH receptor (PTH1R) located on osteoblasts and osteocytes. Activation of PTH1R stimulates adenylate cyclase, elevating cyclic AMP (cAMP) levels and activating protein kinase A (PKA). PKA phosphorylates transcription factors that enhance the expression of bone morphogenetic proteins (BMPs) and RANKL, thereby promoting osteoblastic activity and osteoclastogenesis. Intermittent PTH stimulation preferentially stimulates bone formation, whereas continuous exposure tends to favor resorption. PTH analogs are designed to exploit this intermittent anabolic window, maximizing net bone accrual.

Bisphosphonates

Bisphosphonates possess high affinity for hydroxyapatite, enabling preferential deposition within bone matrix. Upon resorption, bisphosphonates are released into the osteoclast cytosol. Nitrogen‑containing bisphosphonates inhibit farnesyl pyrophosphate synthase (FPPS) in the mevalonate pathway, preventing prenylation of small GTPases essential for osteoclast cytoskeletal organization and vesicular trafficking. This inhibition results in osteoclast apoptosis and impaired resorptive capacity. Non‑nitrogen bisphosphonates incorporate into ATP analogs, disrupting osteoclast energy metabolism and inducing apoptosis. The cumulative effect is a reduction in bone resorption and a consequent increase in BMD.

Denosumab

Denosumab specifically binds RANKL, a cytokine expressed by osteoblasts and osteocytes that ligates the RANK receptor on osteoclast precursors. By sequestering RANKL, denosumab prevents RANKL–RANK interaction, thereby inhibiting osteoclast differentiation, activation, and survival. The blockade of osteoclastogenesis leads to decreased bone turnover and increased BMD. Denosumab’s action is independent of the mevalonate pathway, making it distinct from bisphosphonates.

Selective Estrogen Receptor Modulators (SERMs)

SERMs bind estrogen receptors (ERα and ERβ) with tissue‑specific agonist or antagonist profiles. In bone, SERMs act as ER agonists, increasing OPG production and decreasing RANKL expression, thereby reducing osteoclast activity. In the cardiovascular and breast tissues, SERMs may exhibit antagonist properties, mitigating estrogen‑mediated proliferation. This selective modulation translates into bone preservation without the full spectrum of estrogenic side effects.

Calcitonin

Calcitonin engages the calcitonin receptor (CTR) on osteoclasts, a G protein‑coupled receptor that activates phospholipase C and inositol trisphosphate pathways. This activation leads to reduced osteoclast resorptive activity and promotes osteoclast apoptosis. Calcitonin also exhibits modest effects on calcium excretion by the kidneys, contributing to transient reductions in serum calcium levels.

Hormone Replacement Therapy (HRT)

Estrogen in HRT binds ERs in bone, reducing osteoclast number and activity by upregulating OPG and downregulating RANKL. Progesterone, when combined, mitigates endometrial proliferation and may provide additional bone protective effects through modulation of bone turnover markers. The net effect is a decrease in bone resorption and maintenance of BMD, particularly in postmenopausal women.

Pharmacokinetics

Vitamin D Analogs

Oral vitamin D analogs exhibit variable absorption influenced by dietary fat content and gastric pH. After absorption, they undergo hepatic 25‑hydroxylation to form 25‑hydroxyvitamin D, followed by renal 1α‑hydroxylation to 1,25‑dihydroxyvitamin D in the active form (calcitriol). The half‑life of calcitriol is approximately 15 hours, whereas native vitamin D_3 has a half‑life of 15 days. Metabolism occurs via cytochrome P450 enzymes (CYP24A1) to inactive metabolites excreted in bile. Dosing considerations include body weight, baseline serum 25‑hydroxyvitamin D levels, and renal function. Oral formulations require cautious titration to avoid hypercalcemia.

PTH Analogs

PTH analogs are administered subcutaneously due to poor oral bioavailability. Teriparatide has a plasma half‑life of approximately 1 hour, requiring daily dosing. Abaloparatide displays similar pharmacokinetics with a half‑life of 1.3 hours. Rapid clearance necessitates intermittent dosing schedules to achieve anabolic effects. Renal excretion is minimal; however, caution is advised in severe renal impairment due to potential accumulation of inactive metabolites.

Bisphosphonates

Oral bisphosphonates have low systemic absorption (<1 % of the dose). They bind to hydroxyapatite in cortical and trabecular bone, achieving a prolonged skeletal residence time that can exceed 10 years. Because of the low plasma exposure, bisphosphonates exhibit minimal hepatic metabolism and are primarily excreted unchanged via the kidneys. Intravenous bisphosphonates (e.g., zoledronic acid) achieve higher bioavailability (~100 %) and rapid distribution to bone. Half‑lives vary: alendronate ~10 days, risedronate ~6 weeks, zoledronic acid ~6 months in bone. Dose adjustments for patients with impaired renal function are essential, particularly for IV formulations.

Denosumab

Denosumab is administered subcutaneously at 60 mg intervals. It exhibits a half‑life of approximately 25 days, with a plateau in pharmacodynamic effect after 6 weeks. Denosumab is not metabolized by the liver and is cleared via the reticuloendothelial system; renal clearance is negligible. Consequently, dosing does not require adjustment in renal impairment, although monitoring of serum calcium is recommended due to the risk of hypocalcemia.

SERMs

SERMs are orally administered and undergo extensive hepatic metabolism predominantly via CYP3A4. Raloxifene has a half‑life of ~27 hours, while bazedoxifene’s half‑life is ~48 hours. The bioavailability of raloxifene is approximately 1 % due to extensive first‑pass metabolism, necessitating a high oral dose. Metabolites are excreted in feces and urine. Renal function has minimal effect on pharmacokinetics, but hepatic impairment may reduce clearance.

Calcitonin

Calcitonin can be delivered orally via nasal spray or orally as a tablet. Oral bioavailability is low, but the nasal formulation achieves adequate systemic exposure. The half‑life of calcitonin is approximately 2 hours when administered parenterally. It is metabolized primarily by proteolytic enzymes and excreted via the kidneys. Renal impairment may prolong half‑life; dose adjustments are not typically required but monitoring is advisable.

HRT

Estrogen and progesterone are orally bioavailable; however, first‑pass hepatic metabolism reduces systemic exposure. Transdermal preparations bypass hepatic metabolism, providing more stable serum estrogen levels and reducing hepatic protein synthesis. Half‑lives vary: oral estradiol ~10 hours, transdermal ~2–3 hours. Progesterone metabolites are cleared rapidly. Renal function generally does not influence estrogen pharmacokinetics, whereas hepatic impairment can alter estrogen metabolism and increase the risk of adverse effects.

Therapeutic Uses/Clinical Applications

Osteoporosis

All anti‑osteoporotic agents are approved for the treatment of post‑menopausal osteoporosis, with certain agents also indicated for glucocorticoid‑induced osteoporosis and osteoporosis in men. Bisphosphonates are first‑line therapy, offering high efficacy in reducing vertebral and non‑vertebral fractures. Denosumab serves as an alternative for patients intolerant to bisphosphonates or with contraindications related to renal function. PTH analogs are reserved for severe osteoporosis with high fracture risk, particularly when bisphosphonates and denosumab are contraindicated or ineffective. SERMs are used for bone preservation and prevention of vertebral fractures in women with contraindications to estrogen therapy. Calcitonin provides symptomatic relief of bone pain and modest fracture risk reduction in specific contexts. HRT remains an option for bone preservation in perimenopausal women, balancing bone benefits against systemic risks.

Paget Disease of Bone

Bisphosphonates, especially IV zoledronic acid, are the treatment of choice for Paget disease, effectively normalizing bone turnover markers and reducing skeletal pain. PTH analogs have limited role; denosumab is rarely used due to the need for continuous dosing.

Hypercalcemia of Malignancy

Calcitonin offers rapid, albeit transient, reductions in serum calcium. Denosumab provides sustained suppression of bone resorption, particularly in patients with refractory hypercalcemia. Bisphosphonates are also effective but may be contraindicated in renal impairment.

Bone Metastases

Denosumab and bisphosphonates are employed to reduce skeletal‑related events (fractures, spinal cord compression) in patients with bone metastases from breast, prostate, or other cancers. PTH analogs are generally contraindicated due to hypercalcemia risk.

Other Off‑Label Uses

Calcitonin nasal spray is occasionally used for glucocorticoid‑induced bone loss and for pain control in osteoarthritis. SERMs have been explored for fracture prevention in men with low estrogen levels. Denosumab has been studied for prevention of bisphosphonate‑associated hypocalcemia in renal transplant recipients.

Adverse Effects

Vitamin D Analogs

Serious adverse events are uncommon but include hypercalcemia, hypercalciuria, nephrolithiasis, and, rarely, renal tubular dysfunction. High‑dose supplementation may precipitate vascular calcification, especially in patients with chronic kidney disease.

PTH Analogs

Hypercalcemia is the most frequent serious adverse event, particularly with over‑reliance on therapy. Long‑term use in animal models has suggested an increased risk of osteosarcoma, although the relevance to humans remains uncertain. Other side effects include nausea, injection site reactions, and transient bone pain.

Bisphosphonates

Gastrointestinal irritation, esophageal ulceration, and dysphagia are common with oral bisphosphonates. Osteonecrosis of the jaw (ONJ) and atypical femur fractures appear with long‑term use, particularly in high‑dose IV preparations. Hypocalcemia may occur with potent agents in patients with vitamin D deficiency. Fluclonidine-associated bradycardia and atrial fibrillation are rare but noted with IV bisphosphonates.

Denosumab

Hypocalcemia is a notable adverse event, especially in patients with baseline vitamin D deficiency or renal insufficiency. Skin reactions at the injection site, transient flu‑like symptoms, and increased susceptibility to infections have been reported. Rare cases of osteonecrosis of the jaw and atypical femur fractures have been noted, mirroring bisphosphonate safety concerns.

SERMs

Thromboembolic events, including deep vein thrombosis and pulmonary embolism, are documented risks. Raloxifene has been associated with hot flashes, leg cramps, and an increased risk of endometrial cancer in women with tamoxifen exposure. Other side effects include migraines and mild edema.

Calcitonin

Nausea, flushing, and injection site reactions are common. Long‑term use may be associated with an increased risk of malignancy, though data are conflicting. Hypercalcemia is rare but possible if over‑exposure occurs.

HRT

Increased risks of thromboembolic disease, breast cancer, endometrial hyperplasia (in unopposed estrogen therapy), and gallbladder disease are documented. Cardiovascular events may be reduced in younger women but appear increased in older populations. The balance of benefits and risks depends on individual patient profiles.

Drug Interactions

Bisphosphonates

• Antacids and calcium supplements interfere with absorption; concurrent administration should be avoided.
• Fluoroquinolone antibiotics may potentiate GI irritation.
• Hormone replacement therapy may enhance bone density effects but increase GI side effects.

Denosumab

• Vitamin D deficiency exacerbates hypocalcemia risk; supplementation is recommended.
• Calcitonin may potentiate hypocalcemia.
• Concurrent bisphosphonate therapy is generally discouraged to avoid overlapping bone turnover suppression.

PTH Analogs

• Antacids and calcium supplements diminish absorption and blunt anabolic effects.
• Certain antibiotics (e.g., doxycycline) may reduce bioavailability.

SERMs

• CYP3A4 inhibitors (e.g., ketoconazole) increase serum raloxifene levels, raising thromboembolic risk.
• Oral contraceptives may increase estrogenic side effects.

Calcitonin

• Concurrent use with other hypocalcemic agents (e.g., thiazide diuretics) may exacerbate hypocalcemia.
• Immunomodulatory drugs may alter local immune responses at injection sites.

HRT

• SSRIs and MAO inhibitors increase the risk of thromboembolism when combined with estrogen therapy.
• Cytochrome P450 inducers (e.g., rifampin) reduce estrogen bioavailability.
• Progestins may modify the pharmacodynamics of SERMs.

Special Considerations

Pregnancy and Lactation

Bisphosphonates and denosumab cross the placenta and are detectable in breast milk, potentially affecting fetal and infant bone development; thus, use during pregnancy and lactation is generally contraindicated. Vitamin D analogs may be used cautiously, with monitoring of serum calcium and 25‑hydroxyvitamin D levels. PTH analogs and SERMs lack sufficient safety data and are contraindicated. Calcitonin is considered category B; however, limited evidence suggests minimal risk. HRT is contraindicated during pregnancy and lactation.

Pediatric Considerations

Bisphosphonates are employed for osteogenesis imperfecta and other congenital bone disorders; dosing is weight‑based, and long‑term safety data are emerging. Growth plate involvement necessitates caution with bisphosphonate exposure. PTH analogs are not routinely used in children due to concerns about growth plate effects. SERMs and calcitonin are not approved for pediatric use.

Geriatric Considerations

Age‑related decline in renal function necessitates dose adjustments for bisphosphonates, particularly IV formulations. Fall risk and comorbidities may influence the choice of therapy. Vitamin D deficiency is common; supplementation should be individualized. Monitoring for hypocalcemia with denosumab is critical in frail patients.

Renal Impairment

Bisphosphonate clearance is renal; severe dysfunction (creatinine clearance <30 mL/min) contraindicates IV bisphosphonates and necessitates dose reduction for oral agents. Denosumab is not renally cleared, making it suitable for patients with varying degrees of renal impairment. Vitamin D analogs require monitoring of serum calcium in chronic kidney disease due to altered vitamin D metabolism. PTH analogs may accumulate in severe renal failure, increasing hypercalcemia risk.

Hepatic Impairment

Vitamin D analogs and SERMs undergo hepatic metabolism; mild to moderate hepatic dysfunction may require dose adjustments. Bisphosphonates are not significantly metabolized by the liver, presenting a lower risk. Denosumab is not metabolized hepatically, making it a viable option in hepatic impairment.

Summary/Key Points

• Calcium homeostasis is governed by PTH, vitamin D, calcitonin, and sex steroids, each exerting distinct effects on bone remodeling.
• Anti‑osteoporotic pharmacotherapy is stratified into anabolic (PTH analogs) and anti‑resorptive (bisphosphonates, denosumab, SERMs, calcitonin, HRT) categories.
• Bisphosphonates are first‑line agents for post‑menopausal osteoporosis; denosumab is preferred in patients with renal impairment or bisphosphonate intolerance.
• Adverse effects vary by class: bisphosphonates risk osteonecrosis of the jaw and atypical fractures; denosumab risks hypocalcemia; PTH analogs risk hypercalcemia and potential osteosarcoma; SERMs risk thromboembolism; HRT carries systemic oncologic and cardiovascular risks.
• Drug interactions should be carefully reviewed, particularly with calcium supplements, antacids, CYP3A4 modulators, and hormone therapies.
• Special populations—including pregnant or lactating patients, pediatric patients, the elderly, and those with renal or hepatic impairment—require individualized dosing and monitoring strategies.
• Clinical decision‑making should balance bone protection benefits against safety profiles and patient preferences, integrating current guidelines and emerging evidence.

References

1. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
2. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
3. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
4. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
5. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
6. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
7. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
8. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.